

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Olaparib for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy**

**Batch 36**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was raised during the scoping workshop that older people could have a potential communication problem with the clinicians and that this could affect the care provided.

It was also clarified that this appraisal will look at people and not at women to account for gender reassignment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The Committee will need to consider the characteristics and circumstances of the patients included in any submission of evidence to NICE. It is not expected that the preliminary recommendations in this technology appraisal would have any adverse impact in people with the mentioned characteristics.

It was also clarified that this appraisal will look at people and not at women to account for gender reassignment.

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy

Issue date: September 2014

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope have been agreed to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues have been identified.

**Approved by Associate Director (name):** .....Janet Robertson

**Date:** 26 September 2014